Member Article

Newcastle drug specialists positive about anti-tumour product tests

Newcastle-based drug company e-Therapeutics say a recent clinical test of their anti-tumour product has proved positive.

The firm is hopeful that its ETS2101 (dexanabinol) drug can be used to treat solid turmours, and recent trials have suggested the product could halt tumour growth.

The trials are being conducted across three centres in the UK, lead by principal investigator, professor Ruth Plummer at the Bobby Robson Cancer Centre at the Freeman Hospital in Newcastle upon Tyne.

She said: “We have seen a number of patients who have come onto the study with advanced progressive disease and have stayed on study in some cases for over five months. T

“This suggests that the compound may be halting tumour progression as measured by RECIST criteria. We are excited by this initial observation, and are very keen to continue to escalate the dose to confirm this and explore if further possible anti-tumour effects will be found.”

This was posted in Bdaily's Members' News section by Tom Keighley .